Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth

AI Briefing

• – Verrica Pharmaceuticals reports Q4 and full-year 2025 results with growing sales of YCANTH, a topical treatment for superficial fungal infections.
• – Company cites strong demand for YCANTH, with sales growth driven by expanding dermatology channel.
• – Verrica Pharmaceuticals expects continued momentum in the dermatology market in 2026.